Share data
Our shares at a glance
Since the formation of the Company in 1996, Fresenius Medical Care's ordinary shares have been traded on both the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse – FWB) and the New York Stock Exchange (NYSE). On the NYSE, our ordinary shares are listed in the form of American Depositary Shares (ADS).
Basic share data
| Germany: Frankfurt Stock Exchange/Prime Standard | FME |
| U.S.: New York Stock Exchange (NYSE) | FMS |
| Securities No. (WKN) | 578580 |
| ISIN | DE0005785802 |
| CUSIP No. (NYSE) | 358029106 |
| Xetra | FMEG.DE |
| Frankfurt Stock Exchange | FMEG.F |
| ADR NYSE | FMS.N |
| Xetra | FME GY |
| Frankfurt Stock Exchange | FME GR |
| ADR NYSE | FMS US |
Capital measures
| Date | Measure |
|---|---|
| June 28, 2013 | Conversion of preference shares into ordinary shares |
| December 4, 2012 | 2:1 share split at ADR |
| June 18, 2007 | 1:3 share split |
| October 2, 1996 | First listing on the Frankfurt Stock Exchange |
| October 1, 1996 | First listing on the New York Stock Exchange |
Index membership
Fresenius Medical Care’s shares are listed in the MDAX and are included in a number of other important international share indices, such as the Dow Jones, MSCI and the FTSE.
Key share data
| 2023 | 2022 | 2021 | 2020 | 2019 | ||
|---|---|---|---|---|---|---|
| Year-end closing price | in € | 37.96 | 30.57 | 57.14 | 68.20 | 65.96 |
| Year-high | in € | 49.33 | 63.56 | 70.96 | 79.00 | 76.32 |
| Year-low | in € | 30.25 | 26.26 | 52.78 | 56.00 | 55.58 |
| Market capitalization1 | in € M | 11,138 | 8,970 | 16,742 | 19,974 | 20,081 |
| Number of shares2 | in M shares | 293.4 | 293.4 | 293.00 | 292.86 | 304.44 |
| Dividend per share | in € | 1.19 | 1.12 | 1.353 | 1.34 | 1.20 |
| Dividend yield4 | in % | 3.13 | 3.66 | 2.363 | 1.76 | 1.82 |
| Total dividend payout | in € M | 349 | 329 | 3963 | 392 | 358 |
| Basic earnings per ordinary share (EPS) | in € | 1.70 | 2.30 | 3.31 | 3.96 | 3.96 |
1 Based on shares outstanding.
2 Shares outstanding on December 31 of the respective year.
3 Based on the proposal to be approved by the Annual General Meeting on May 12, 2022.
4 With reference to the respective year-end.
Contact us for further information
